3 active not recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation Onvansertib, FOLFIRI, Bevacizumab - Metastatic Colorectal Cancer, CRC | Phase 2 | Active not recruiting | Cardiff Oncology | 110 | 2024-02-27 | 2026-06-16 |
| A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression A2B530, xT-Onco with HLA-LOH Assay - Solid Tumor, Adult, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | A2 Biotherapeutics Inc. | 160 | 2023-04-28 | 2025-04-25 |
| Study to Evaluate D-1553 in Subjects With Solid Tumors D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other - Solid Tumor, Adult, NSCLC | Phase 1 / Phase 2 | Active not recruiting | InventisBio Co., Ltd | 180 | 2020-10-02 | 2025-03-18 |
Colorectal Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1)
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms by Site (2) · Rectal Diseases (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Lung Diseases (1)
Bevacizumab (1) · Cetuximab (1) · Folfox protocol (1) · IFL protocol (1) · onvansertib (1) · pembrolizumab (1)
A2 Biotherapeutics Inc. (1) · Cardiff Oncology (1) · InventisBio Co., Ltd (1)
United States (3) · Australia (1) · South Korea (1) · Taiwan (1)
Eric Ng, MD (1)